Orphan drugs

In order to search for new opportunities in the biotech sector Genetrix aims to reconcile economic interest with social commitment within new market niches.

Our group develops clinical research programs for the treatment of rare (orphan) diseases, which affect no more than five in every 10,000 people in European Union (EU).

Fenix Biotech, a Genetrix company, is developing a nanoencapsulation technology for treating monogenic diseases with potential to be considered as orphan drugs in various indications.